Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway

Oncogene

Volumn 30, Issue 45, 2011, Pages 4578-4589

  Park, J H ^a   Lee, J Y ^a   Shin, D H ^a   Jang, K S ^a   Kim, H J ^a   Kong, G ^a  

^a Hanyang University   (South Korea)

Author keywords

Akt; angiogenesis; Mel 18; polycomb group proteins

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB GROUP PROTEIN; PROTEIN MEL 18; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CHROMOSOME 10; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED NOD; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80755140181     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.174     Document Type: Article

References (48)

1. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. (2005). Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280: 35195-35202. (Pubitemid 41532706)
2. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973. (Pubitemid 26382753)
3. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ et al. (2002). Phosphorylation of HDM2 by Akt. Oncogene 21: 1955-1962. (Pubitemid 34270884)
4. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA et al. (2010). HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-2301.
5. Bardos JI, Chau NM, Ashcroft M. (2004). Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol Cell Biol 24: 2905-2914. (Pubitemid 38381279)
6. Brahimi-Horn MC, Pouyssegur J. (2009). HIF at a glance. J Cell Sci 122: 1055-1057.
7. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868. (Pubitemid 29165088)
8. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC et al. (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
9. Davis R, Singh KP, Kurzrock R, Shankar S. (2009). Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22: 1473-1478.
10. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K et al. (1999). Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914. (Pubitemid 29158534)
11. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. (2008). PTEN regulates p300-dependent hypoxia-inducible factor 1 tran-scriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA 105: 2622-2627. (Pubitemid 351520563)
12. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. (2007). PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 19: 2487-2497. (Pubitemid 47531929)
13. Flugel D, Gorlach A, Michiels C, Kietzmann T. (2007). Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27: 3253-3265. (Pubitemid 46685205)
14. Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY et al. (2010). Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Ann Oncol 21: 2361-2369.
15. Guo WJ, Datta S, Band V, Dimri GP. (2007a). Mel-18, a polycomb group protein, regulates cell proliferation and senescence via tran-scriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 18: 536-546. (Pubitemid 46213222)
16. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V et al. (2007b). Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 67: 5083-5089. (Pubitemid 46997242)
17. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U et al. (2008). High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarci-nomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10: 674-679. (Pubitemid 351883883)
18. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. (1999). The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168. (Pubitemid 29050921)
19. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM et al. (2005). STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19: 1296-1298. (Pubitemid 41113728)
20. Jung JH, Choi HJ, Maeng YS, Choi JY, Kim M, Kwon JY et al. (2010). Mel-18, a mammalian Polycomb gene, regulates angiogenic gene expression of endothelial cells. Biochem Biophys Res Commun 400: 523-530.
21. Kim HJ, Chung H, Yoo YG, Kim H, Lee JY, Lee MO et al. (2007). Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha. Mol Cancer Res 5: 321-329. (Pubitemid 46706994)
22. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC et al. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273. (Pubitemid 40568685)
23. Lee JY, Jang KS, Shin DH, Oh MY, Kim HJ, Kim Y et al. (2008). Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 68: 4201-4209.
24. Lee YM, Lim JH, Chun YS, Moon HE, Lee MK, Huang LE et al. (2009). Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis 30: 1768-1775.
25. Li W, Tan D, Zhang Z, Liang JJ, Brown RE. (2008). Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20: 713-719.
26. Li X, Lin G, Wu B, Zhou X, Zhou K. (2007). Overexpression of PTEN induces cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells. Acta Biochim Biophys Sin (Shanghai) 39: 745-750. (Pubitemid 47631037)
27. Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A et al. (2009). PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 331: 161-171.
28. Maxwell PH, Pugh CW, Ratcliffe PJ. (2001a). Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11: 293-299. (Pubitemid 32480296)
29. Maxwell PH, Pugh CW, Ratcliffe PJ. (2001b). Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation. Exp Nephrol 9: 235-240. (Pubitemid 32620207)
30. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M et al. (2010). Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9: 985-995.
31. Pugh CW, Ratcliffe PJ. (2003). The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 13: 83-89. (Pubitemid 36269184)
32. Qian T, Lee JY, Park JH, Kim HJ, Kong G. (2010). Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex. Oncogene 29: 5818-5827.
33. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44. (Pubitemid 30051577)
34. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. (1999). p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcrip-tional activity of HIF-1. J Biol Chem 274: 32631-32637. (Pubitemid 129535289)
35. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. (2004). Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279: 45643-45651. (Pubitemid 39491552)
36. Tan M, Gu Q, He H, Pamarthy D, Semenza GL, Sun Y. (2008). SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1 alpha ubiquitination and degradation. Oncogene 27: 1404-1411. (Pubitemid 351317467)
37. Tanimoto K, Makino Y, Pereira T, Poellinger L. (2000). Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309. (Pubitemid 30623741)
38. Tian T, Nan KJ, Wang SH, Liang X, Lu CX, Guo H et al. (2010). PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and-independent mechanisms in HepG2 cells: PTEN regulates angiogenesis in HepG2. Carcinogenesis 31: 1211-1219.
39. Torres J, Pulido R. (2001). The tumor suppressor PTEN is phospho-rylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998. (Pubitemid 32096519)
40. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156. (Pubitemid 46048885)
41. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. (2004). Stem cells and cancer; the polycomb connection. Cell 118: 409-418. (Pubitemid 39485661)
42. Van Themsche C, Leblanc V, Parent S, Asselin E. (2009). X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitina-tion, content, and compartmentalization. J Biol Chem 284: 20462-20466.
43. Vemula S, Shi J, Hanneman P, Wei L, Kapur R. (2010). ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115: 1785-1796.
44. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139. (Pubitemid 46048884)
45. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C et al. (2009). Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119: 650-660.
46. Yee Koh M, Spivak-Kroizman TR, Powis G. (2008). HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 33: 526-534.
47. Yoo YG, Yeo MG, Kim DK, Park H, Lee MO. (2004). Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha. J Biol Chem 279: 53365-53373. (Pubitemid 40051842)
48. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545. (Pubitemid 30183422)